Navigation Links
Beckman Coulter Announces Third Quarter 2009 Results
Date:10/29/2009

edged instrument are recognized in earnings. As a result, we recognized a gain of approximately $10.9 million and $19.6 million for the quarter and nine months ended September 30, 2009, respectively, which is reflected within non-operating income in our consolidated statement of earnings. Additionally in the third quarter of 2009, we recorded a $2.2 million foreign currency gain related to the days between obtaining the funds (denominated in Yen) and remitting the funds to purchase ODS. Furthermore, we recorded an exchange gain of $4.9 million on settlement of intercompany loans related to the funding of the ODS acquisition in the quarter ended September 30, 2009. c) Fair market value inventory adjustment - We recorded an $8.8 million charge during the third quarter of 2009 related to the fair value of acquired inventory in connection with the ODS acquisition, as a portion of the acquired inventory was sold during the third quarter. A similar charge for $1.0 million was incurred during the first quarter of 2008 in connection with our acquisition of the flow cytometry business of Dako A/S related to the fair value of acquired inventory sold in the first quarter. d) Inventory write-off - We recorded a charge of $1.6 million related to inventory written off due to discontinuation of certain product lines in the third quarter of 2009. e) Interest expense on debt offering - On May 26, 2009, we issued $250 million principal amount of the Company's 6% Senior Notes due 2015 and $250 million principal amount of the Company's 7% Senior Notes due 2019 (the "Notes"). The proceeds from the Notes were used to partially fund the ODS acquisition. During the third quarter and nine months ended September 30, 2009, we incurred approximately $2.4 million and $5.6 milli
'/>"/>
SOURCE Beckman Coulter, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine technology :

1. Beckman Coulter Announces Licensing Agreements for Molecular Tests with National University of Ireland, Galway
2. Beckman Coulter Buys Out Royalty Obligation for Preeclampsia Markers
3. Beckman Coulter to Present at Upcoming Healthcare Conferences
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... CHAGRIN FALLS, Ohio , July 30, 2015 /PRNewswire/ ... in his OMTEC® 2015 keynote address last month that ... business models in order to gain the efficiencies—and develop ... future. Dr. Barsoum,s comments were preceded by ... Tornier, avid entrepreneur and OMTEC moderator, who stressed that ...
(Date:7/30/2015)... , July 30, 2015 ... research report with market overview, trends, DRO ... porter analysis, recent developments, competitive scenario and ... Industry Insight: Biosensors Market Development and Demand ... http://photos.prnewswire.com/prnh/20150727/756778 ) Explore more ...
(Date:7/30/2015)... 2015 Vermillion, Inc. (VRML), a ... announced today it will report its second ... close on Thursday, August 13, 2015, followed ... at 4:30pm Eastern.Conference Call and Webcast:  ... Pacific  Domestic: , 888-430-8691International: ...
Breaking Medicine Technology:Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 2Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 3Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 4Global Biosensors Market (Size of $12,964 Million in 2014) to Witness 10% CAGR During 2015 - 2020 5
... Analysis of SPIRIT II and SPIRIT III Data Confirms Patients ... Death, a Heart Attack or a ... TAXUS(R) at Two Years, WASHINGTON, Oct. 13 Data ... randomized clinical,trials demonstrated that the XIENCE V(TM) Everolimus Eluting Coronary ...
... Class, of Stent with Polyzene(R)-F Surface ... for Long-Term,Dual Antiplatelet Therapy, WASHINGTON, ... today,s,"Innovative Devices and Futuristic Therapies" session ... (TCT) scientific,symposium, sponsored by the Cardiovascular ...
Cached Medicine Technology:Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 2Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 3Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 4Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years 512-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 212-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 312-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions 4
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark Software, ... LeadingAge’s Center for Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The whitepaper ... care providers understand the benefits of using medication management technologies . ...
(Date:7/31/2015)... McLean, VA (PRWEB) , ... July 31, 2015 , ... ... solution at OSEHRA 2015. , What is HITaaS? Health IT as a Service (HITaaS) ... (IaaS) and software as a service (SaaS). , HITaaS manages all aspects ...
(Date:7/31/2015)... ... 31, 2015 , ... Physical therapy for knee osteoarthritis is an important ... It keeps the patient from doing what they want or need to do. The patient ... using the stairs. The patient's exercise regime may be limited by the pain in their ...
(Date:7/31/2015)... ... , ... New Energy Works Timberframers invites the public to join their timber ... from 9am – 12pm. Timber frame raisings are special, celebrating both craft ... the culmination of months of effort, planning, fundraising, and dreaming takes shape. , ...
(Date:7/31/2015)... ... ... The Radiology Business Management Association’s 2015 Fall Educational Conference ... Care: A View From Capitol Hill” on Sunday, Sept. 27, 2015, in Austin, Tex. ... has a special understanding of the real world impact of health care policy issues,” ...
Breaking Medicine News(10 mins):Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3
... frozen ready meals including 20 Asda own brand, 4 Sainsbury’s ... may contain small pieces of glass. Customers are also being ... ,The products came from Rye Valley Foods in Carrickmacross, a ... the country's biggest food processors. The company said pieces of ...
... group from Los Angeles has pressed upon Viagra manufacturers to ... pushes the drug’s use as a recreational drug. ... by gay and bisexual men who are also patronizing methamphetamine, ... risks. The AIDS Healthcare Foundation is especially worried that this ...
... after being administered DPT (diphtheria, pertussis and tetanus) injection Saturday. ... ,According to official sources, the deaths took place ... km from here. Twelve children have been admitted to Ara ... programme was launched for children below one year of age. ...
... Breast and Bowel Project (NSABP) B-33 study, presented ... showed that// postmenopausal women with hormone receptor-positive breast ... tamoxifen were 56% less likely to have a ... placebo (P=0.004). ,“Aromasin provided patients with ...
... The prescription for an anti-smoking pill Zyban, given by a ... ,Smokers who were residents of Glasgow, were trying to ... pill. This was mistakenly read as Viagra due to a ... Greater Glasgow and Clyde said , due to an error ...
... that women treated for ovarian cancer are at increased ... their tumor cells have high// levels of a binding ... death, both hallmarks of malignancy. ,“Now there’s ... tissue removed during surgery might identify women most at ...
Cached Medicine News:Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 2Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 3Health News:New Study Shows Efficacy of AROMASIN on Early Breast Cancer 4Health News:'Clumping' Protein Linked to Return of Ovarian Cancer 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: